Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab effects on small airway pathology in severe asthma
NL-OMON58077Not yet recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of tezepelumab in asthma, sponsored by Maastricht University Medical Center+. Primary endpoint: Change in specific image-based airway volumes and resistance at 12 weeks. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON58077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58077.